International Working Group (IWG) 2 Criteria for Alzheimer's Disease Diagnosis

ورودی‌های بالینی بیمار

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
iwg2 diagnosis
—diagnosis
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • Typical ADtypical_ad–typical_ad
  • Atypical ADatypical_ad–atypical_ad
  • Mixed ADmixed_ad–mixed_ad
  • Asymptomatic at Riskasymptomatic_at_risk–asymptomatic_at_risk
Direct Clinical Answer

The International Working Group (IWG) 2 Criteria for Alzheimer's Disease Diagnosis calculates quantifying neurological deficit severity, stroke volume, and reperfusion therapy eligibility. Key inputs include clinical phenotype. Scores guide initiating intravenous thrombolysis, activating endovascular thrombectomy pathways, or secondary prevention protocols. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

Diagnoses Alzheimer's disease (AD) using revised research diagnostic criteria that integrate clinical phenotypes with pathophysiological biomarkers. The IWG-2 criteria represent a major advancement over previous diagnostic approaches by requiring both an appropriate clinical AD phenotype (typical or atypical) and pathophysiological biomarker evidence of Alzheimer pathology. This framework covers the full disease spectrum from asymptomatic at-risk individuals to typical and atypical AD presentations. The IWG-2 criteria distinguish between pathophysiological markers (CSF Aβ1-42, T-tau, P-tau, amyloid PET) used for diagnosis and topographical markers (volumetric MRI, FDG-PET) used for progression monitoring. This diagnostic tool enables earlier and more accurate identification of AD across the disease continuum, facilitating appropriate treatment planning and research enrollment.

Clinical Indication

The International Working Group (IWG) 2 Criteria for Alzheimer's Disease Diagnosis is indicated for bedside clinical practice to support Diagnoses Alzheimer's disease (AD) using revised research diagnostic criteria that integrate clinical phenotypes with pathophysiological biomarkers. The IWG-2 criteria represent a major advancement over previous diagnostic approaches by requiring both an appropriate clinical AD phenotype (typical or atypical) and pathophysiological biomarker evidence of Alzheimer pathology. This framework covers the full disease spectrum from asymptomatic at-risk individuals to typical and atypical AD presentations. The IWG-2 criteria distinguish between pathophysiological markers (CSF Aβ1-42, T-tau, P-tau, amyloid PET) used for diagnosis and topographical markers (volumetric MRI, FDG-PET) used for progression monitoring. This diagnostic tool enables earlier and more accurate identification of AD across the disease continuum, facilitating appropriate treatment planning and research enrollment.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients presenting with acute neurological deficits, acute ischemic stroke, intracranial hemorrhage, seizures, or altered mental status. Clinical application is indicated across Comprehensive stroke centers, acute neurovascular units, neuro-ICU, and emergency neurology services.

Limitations & Contraindications

Stroke mimics including severe hypoglycemia, Todd postictal paresis, and hemiplegic migraine must be ruled out prior to intravenous thrombolysis.

Clinical Pearls & Action Plan

Time is brain; rapid determination of Last Known Well time and baseline functional status dictates reperfusion eligibility.

Formula & Variables:

Diagnosis requires: Clinical AD phenotype (typical/atypical/mixed) + Pathophysiological biomarker evidence (CSF Aβ1-42 ↓ and/or T-tau ↑ and/or P-tau ↑ and/or Amyloid PET +). Topographical markers (MRI, FDG-PET) used for progression monitoring only.

Input Parameters

NameTypeRequiredDescription
clinical_phenotypestringYesClinical presentation pattern of cognitive impairment
memory_impairmentstringYesPresence of episodic memory impairment (typical AD pattern)
cognitive_domains_affectedstringYesNumber of cognitive domains significantly impaired
csf_amyloid_betastringYesCSF Aβ1-42 levels (pathophysiological biomarker)(pg/mL)
csf_taustringYesCSF total tau (T-tau) levels (pathophysiological biomarker)(pg/mL)
csf_ptaustringYesCSF phosphorylated tau (P-tau) levels (pathophysiological biomarker)(pg/mL)
amyloid_petstringYesAmyloid PET imaging results (pathophysiological biomarker)
functional_declinestringYesProgressive functional decline in activities of daily living

Score Interpretation & Guidance

RangeStageDescription
typical_ad–typical_adTypical ADMeets criteria for typical Alzheimer's disease
atypical_ad–atypical_adAtypical ADMeets criteria for atypical Alzheimer's disease
mixed_ad–mixed_adMixed ADMeets criteria for mixed Alzheimer's disease
asymptomatic_at_risk–asymptomatic_at_riskAsymptomatic at RiskAsymptomatic at risk for Alzheimer's disease
insufficient_criteria–insufficient_criteriaInsufficient CriteriaDoes not meet IWG-2 criteria for AD diagnosis

Evidence-Based References (EBM)

  • Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014 Jun;13(6):614-29. doi: 10.1016/S1474-4422(14)70090-0.DOI: 10.1016/S1474-4422(14)70090-0
  • Jack CR Jr, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.DOI: 10.1016/j.jalz.2018.02.018
  • Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimers Dement. 2016 Mar;12(3):292-323. doi: 10.1016/j.jalz.2016.02.002.DOI: 10.1016/j.jalz.2016.02.002

Related calculators